<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00280631</url>
  </required_header>
  <id_info>
    <org_study_id>TLK199.1101</org_study_id>
    <nct_id>NCT00280631</nct_id>
  </id_info>
  <brief_title>Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)</brief_title>
  <official_title>Phase 1-2a Dose-Ranging Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Telik</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Telik</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of TLK199 Tablets in
      patients with Myelodysplastic Syndrome (MDS)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 1-2a study is an open label, dose‑ranging study of TLK199 Tablets in patients with
      all World Health Organization or French‑American‑British classification types of
      myelodysplastic syndrome (MDS). In Phase 1, the safety, pharmacokinetics, and hematologic
      response rate with TLK199 Tablets will be evaluated. The Phase 1 dose‑ranging stage is
      designed to determine the maximum tolerated dose or optimal biologic dose of TLK199 Tablets.
      Evaluation of the pharmacokinetics of TLK199 Tablets will be conducted. In Phase 1, an
      additional 12 patients will undergo pharmacokinetic evaluation under fed conditions at the
      selected Phase 2a dose. In Phase 2a, further safety and hematologic responses by the modified
      International Working Group MDS response criteria will be studied.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose or Optimal Biologic Dose</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Pharmacokinetic Parameters, Hematologic Response Parameters</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation Study of TLK199 Tablets From 200 mg Per day To 6000 mg Per Day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezatiostat Hydrochlorine</intervention_name>
    <description>Oral Tablets in 2 Divided Doses, Dose Escalation From 200 mg Per Day to 6000 mg Per Day on Days 1-7 of each 21 Day Cycle.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>TLK199 Tablets</other_name>
    <other_name>Telintra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of MDS

          -  Documented significant cytopenia for at least 2 months

          -  Adequate liver and kidney function

          -  Ineligible for stem cell bone marrow transplantation

          -  At least 18 years of age

          -  Discontinuation of growth factors (e.g., G-CSF) within 3 weeks of study entry

        Exclusion Criteria:

          -  Prior bone marrow transplant

          -  Failure to recover from any prior surgery or any major surgery within 4 weeks of study
             entry

          -  Pregnant or lactating women

          -  Other investigational drugs within 14 days of study entry

          -  Chemotherapy, radiotherapy or immunotherapy within 14 days of study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail Brown, MD</last_name>
    <role>Study Director</role>
    <affiliation>Telik</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loyola University Chicago-Cardinal Bernardin Cancer Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts (UMass) Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2006</study_first_submitted>
  <study_first_submitted_qc>January 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2006</study_first_posted>
  <last_update_submitted>May 30, 2012</last_update_submitted>
  <last_update_submitted_qc>May 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

